Voyager Therapeutics (NASDAQ:VYGR) Issues Earnings Results, Beats Estimates By $0.08 EPS

Voyager Therapeutics (NASDAQ:VYGR) announced its earnings results on Thursday. The company reported ($0.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.08, Zacks reports. The firm had revenue of $3.17 million during the quarter, compared to analyst estimates of $4.52 million. Voyager Therapeutics had a negative net margin of 312.63% and a negative return on equity of 54.82%.

Voyager Therapeutics Price Performance

Shares of NASDAQ VYGR opened at $3.27 on Friday. The stock has a market capitalization of $197.57 million, a price-to-earnings ratio of -1.82 and a beta of 1.31. The business has a 50-day moving average of $3.40 and a 200-day moving average of $3.73. Voyager Therapeutics has a fifty-two week low of $2.93 and a fifty-two week high of $5.55.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Wexford Capital LP acquired a new position in Voyager Therapeutics during the third quarter worth $42,000. CIBC Asset Management Inc bought a new stake in shares of Voyager Therapeutics in the 4th quarter valued at about $45,000. Coldstream Capital Management Inc. acquired a new stake in Voyager Therapeutics in the 3rd quarter valued at about $55,000. Virtu Financial LLC acquired a new stake in Voyager Therapeutics in the 3rd quarter valued at about $93,000. Finally, Occudo Quantitative Strategies LP bought a new position in Voyager Therapeutics during the second quarter worth about $78,000. 48.03% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on VYGR. HC Wainwright restated a “buy” rating on shares of Voyager Therapeutics in a report on Monday, July 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Voyager Therapeutics in a report on Monday, July 13th. Finally, Wall Street Zen downgraded Voyager Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $16.50.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.